Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced that its state-of-the-art clinical laboratory in Houston, Texas, has successfully earned a Certificate of Accreditation from the Centers for Medicare & Medicaid Services (CMS). The accreditation follows a...
CNSide Diagnostics, a leader in precision diagnostics for central nervous system (CNS) cancers, is proud to announce the addition of Tramel Pennie to its growing team as Senior Laboratory Technician. Tramel brings valuable experience in clinical laboratory operations...
Expert Insights on LM Care CNSide Diagnostics is proud to share the recording of last month’s expert panel on leptomeningeal metastases (#LM) from the Society for Neuro-Oncology (SNO)/American Society of Clinical Oncology (ASCO) CNS Metastases Conference. Leading...
Precision Medicine and Companion Diagnostics In a recent Medical Device Network interview, Russell Bradley, President and General Manager of CNSide Diagnostics, emphasized the essential role of companion diagnostics (CDx) in advancing targeted cancer therapies. As...
Collaboration Spotlight: Advancing Leptomeningeal Metastases Research Last week, the leadership teams from Plus Therapeutics and CNSide Diagnostics came together onsite at #SNOASCO2025 in Baltimore, Maryland. Their jointly sponsored symposium on leptomeningeal...
Expert Insights on CNS Metastases Russell Bradley, President and General Manager of CNSide Diagnostics, recently sat down with Pharmafile to discuss one of oncology’s greatest challenges: central nervous system (CNS) cancer metastases. CNS metastases, including...
Mark Your Calendars: A Must-Attend Symposium on LM We’re excited to announce that CNSide Diagnostics will participate in the upcoming 2025 SNO/ASCO CNS Metastases Conference, held in Baltimore, Maryland. Date & Time: Thursday, August 14, 2025, at 6:15 PMLocation:...
Our Mission: Transforming Cancer Diagnostics At CNSide Diagnostics, our mission is clear: to improve patient outcomes by delivering cutting-edge diagnostics that empower oncologists with personalized, effective treatment strategies. Cancer that spreads to the central...
Precision Diagnostics for CNS Metastases Emerging data highlights the potential of the CNSide® cerebrospinal fluid (CSF) assay platform as a sensitive and precise tool for diagnosing and longitudinally monitoring leptomeningeal disease (LMD), a life-threatening...